Tian-Xin Chen

Dr. Tian-Xin Chen

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in International Orthopaedics
Verified
Journal Article
Closed access
PDF file
TCTian-Xin Chen
Tian-Xin Chen
MYMei-Qi Yu
Mei-Qi Yu
TDTing-Ting Dong
Ting-Ting Dong
YLYan Li
Yan Li
SZSheng Zhang
Sheng Zhang
LZLei Zhang
Lei Zhang

6 June 2024 in Asian Journal of Surgery
Verified
Journal Article
Open access
TCTian-Xin Chen
Tian-Xin Chen
ZZZhi-Long Zhang
Zhi-Long Zhang
YZYu-Qi Zhu
Yu-Qi Zhu
SYSheng-Ping Yang
Sheng-Ping Yang

27 June 2025 in International Journal of Surgery
Verified
Journal Article
Open access
YZYU ZHANG
YU ZHANG
TCTian-Xin Chen
Tian-Xin Chen
TDTing-Ting M.D Dong
Ting-Ting M.D Dong
JZJIANHU ZHENG
JIANHU ZHENG
SZSheng M.M. Zhang
Sheng M.M. Zhang
LZLei Zhang
Lei Zhang
Background: Both bicompartmental knee arthroplasty (BKA) and total knee arthroplasty (TKA) are viable treatment options for patients with osteoarthritis affecting the medial tibiofemoral and patellofemoral compartments. The efficacy and safety of both surgical procedures were assessed through a systematic review and meta-analysis. Methods: This review was registered in the PROSPERO database and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement, as well as the Cochrane Handbook for Systematic Reviews of Interventions. A comprehensive systematic literature search was conducted across the PubMed, Embase, Web of Science, and Cochrane Library databases, with a cut-off date of April 1, 2025, to identify relevant studies. We included randomized controlled trials (RCTs) and cohort studies comparing BKA with TKA for treating patients with osteoarthritis in the medial tibiofemoral and patellofemoral compartments. Studies from all countries and in any language were considered. Eligible studies were assessed for quality, data extracted, and meta-analyzed using Review Manager 5.4 software. Results: Based on strict inclusion and exclusion criteria, 14 studies, including 4 RCTs and 10 cohort studies involving 671 patients, were included in this analysis. The Knee Society (KSS) total score (mean difference [MD] = 2.57; 95% confidence interval [CI]: 0.55, 4.60; P = 0.01) and the University of California at Los Angeles score (MD = 0.56; 95% CI: 0.23, 0.89; P = 0.0009) were significantly better in the BKA group than in the TKA group; no significant differences in KSS function score were observed between the two groups at 6 and 12 months (6 months: MD = −0.61; 95% CI: −5.35, 4.13; P = 0.80; 12 months: MD = 4.72; 95% CI: −1.50, 10.94; P = 0.14), but the BKA group had higher score than the TKA group at more than 24 months (MD = 4.04; 95% CI: −0.26, 8.34; P = 0.07). Patients in the BKA group demonstrated greater joint mobility than those in the TKA group at 6 months, 12–24 months, and more than 24 months (6 months: MD = 8.00; 95% CI: 4.68, 11.31; P < 0.00001; 12–24 months: MD = 13.92; 95% CI: 9.80, 18.04; P < 0.00001; >24 months: MD = 4.63; 95% CI: 1.34, 7.91; P = 0.006). The Western Ontario and McMaster Universities Osteoarthritis Index physical function score (MD = 7.30; 95% CI: 4.34, 10.26; P < 0.00001) was higher than the TKA group in the early period. The hip–knee–ankle angle was greater in the TKA group than in the BKA group (MD = −2.94; 95% CI: −3.50, −2.32; P < 0.00001). Additionally, surgical blood loss (MD = −1.23; 95% CI: −1.58, −0.88; P < 0.00001) and hospital stay were lower in the BKA group than in the TKA group ( P < 0.05). No significant differences were found between the two groups in KSS joint score at three-time points (6 months: MD = 2.32; 95% CI: −2.31, 6.94; P = 0.33; 12 months: MD = −3.85; 95% CI: −8.79, 1.08; P = 0.13; >24 months: MD = 0.28; 95% CI: −3.26, 4.23; P = 0.80), Oxford Knee score (MD = 1.56; 95% CI: -2.40, 5.51; P = 0.44), the Short-Form-36 Health Survey (Mental Component Summary: MD = 0.10; 95% CI: −3.05, 3.25; P = 0.95; MD = −1.40; 95% CI: −3.84, 1.04; P = 0.26), timed up and go (MD = −0.28; 95% CI: −0.65, 0.10; P = 0.15), revision rate (MD = 1.92; 95% CI: 0.74, 4.98; P = 0.18), or postoperative complications (MD = 2.03; 95% CI: 0.45, 9.17; P = 0.36). Conclusion: Our results suggest that BKA may be an alternative surgical option for patients with medial-patellofemoral osteoarthritis compared to TKA, but further studies are needed to confirm this conclusion and evaluate long-term outcomes and cost-effectiveness.

27 July 2024 in Asian Journal of Surgery
Verified
Journal Article
Open access
TCTian-Xin Chen
Tian-Xin Chen
ZZZhi-Long Zhang
Zhi-Long Zhang
YZYu-Qi Zhu
Yu-Qi Zhu
SZShuai Zhang
Shuai Zhang

20 April 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
CSChengcheng Song
Chengcheng Song
TCTaowu Chen
Taowu Chen
SYSijia Yu
Sijia Yu
THTianjiao Huang
Tianjiao Huang
TCTian-Xin Chen
Tian-Xin Chen
YLYanchen Liang
Yanchen Liang
Background: Multiple myeloma (MM) typically evolves from monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Its progression is accompanied by significant tumor heterogeneity and immune microenvironment remodeling, and MM remains largely incurable despite therapeutic advances. Elucidating cellular heterogeneity and regulatory mechanisms involved in disease progression is critical for understanding MM pathogenesis. Methods: Single-cell RNA sequencing (scRNA-seq) provides important support for systematically elucidating the molecular mechanisms and immune regulatory pathways associated with the progression of MM. The scRNA-seq datasets from healthy donors (HD), MGUS, SMM, and MM patients were obtained from the GEO database to analyze plasma cell transcriptional heterogeneity within the bone marrow microenvironment. Plasma cell differentiation trajectories were inferred using pseudotime analysis, and intercellular communication and transcription factor regulatory networks were predicted using CellChat and SCENIC analyses. In addition, functional validation of ELK3 was performed in vitro using MM cell lines RPMI 8226 and U266. Results: In this work, we used scRNA-seq to thoroughly evaluate the heterogeneity of MM. We identified a tumor-associated plasma cell subtype, C4 TTN+ plasma cell subtype, which was predominant in SMM and MM and was significantly enriched throughout the intermediate and final phases of differentiation. We hypothesized that C4 TTN+ plasma cell subtype may be associated with the progression of MM. We also found that the TGFb signaling pathway played a key role in the interaction between C4 TTN+ plasma cell subtype and various cell types within the TME. Furthermore, in vitro experiments validated the positive regulatory effects of ELK3 on plasma cell proliferation, migration, and cell viability in MM. Conclusion: In summary, this study, based on scRNA-seq analysis, identified a C4 TTN+ plasma cell subtype potentially associated with ELK3 . This subtype may be associated with progression and immune evasion in MM, thereby providing a potential new direction for targeted immunotherapeutic strategies in MM.